US 11,078,236 B2 · Selenium-based therapies

Abstract

This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.

Claims3

Dependent claims

A compound comprising:

(a) a selenium-containing portion, wherein the selenium-containing portion consists of a C-terminus domain selenoprotein P fragment consisting of the sequence UKUNLN (SEQ ID NO:28);
(b) linked to a Tat transduction domain.

Dependencies are inferred from the claim text.

Facts

Application

15/969,742Filed 2 May 2018 · us provisional application

Priority

2 May 2017

Published

US 2018/0327456 A115 Nov 2018

Granted

3 Aug 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 14/001
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: by chemical synthesis
A61K 31/095
Medicinal preparations containing organic active ingredients: sulfur, selenium, or tellurium compounds, e.g. thiols
A61K 38/10
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 12 to 20 amino acids
A61K 38/16
Medicinal preparations containing peptides: peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Selenium-based therapies

Life of this patent

Selenium-based therapies

Life of this patent

Abstract

Claims3